Frequently Asked Questions
The market is segmented based on Segmentation, By Type (Leukaemia, Lymphoma, and Myeloma), Treatment (Medication, Radiation Therapy, Stem Cell Transplant, and Others), Diagnosis (Blood Tests, Bone Marrow Biopsy, Urine Tests, and Imaging Tests), Dosage Forms (Capsule, Tablets, Injections, and Others), End-Users (Hospitals, Specialty Clinics, Homecare, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others) – Industry Trends and Forecast to 2031
.
The Global Blood Cancer Drug Market size was valued at USD 5.02 USD Million in 2023.
The Global Blood Cancer Drug Market is projected to grow at a CAGR of 5.6% during the forecast period of 2024 to 2031.
The major players operating in the market include F. Hoffmann La Roche , Mylan N.V., Teva Pharmaceutical Industries , Sanofi, Pfizer , GlaxoSmithKline plc, Novartis AG, Bayer AG, Eli Lilly and Company, Merck & Co. , Allergan, AstraZeneca, Johnson & Johnson Private Limited, Cipla , Abbott, AbbVie , Merck KGaA, LEO Pharma A/S, Bausch Health Companies , Sun Pharmaceutical Industries , Aurobindo Pharma, Lupin, Hikma Pharmaceuticals PLC, Fresenius Kabi AG, Amneal Pharmaceuticals LLC..
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
